Literature DB >> 18427979

Effect of Coenzyme Q(10), Riboflavin and Niacin on Tamoxifen treated postmenopausal breast cancer women with special reference to blood chemistry profiles.

Srinivasan Yuvaraj1, Vummidi Gridhar Premkumar, Palanivel Shanthi, Kothandaraman Vijayasarathy, Sitthu Govindaswamy Dinakaran Gangadaran, Panchanatham Sachdanandam.   

Abstract

BACKGROUND: Tamoxifen (TAM) a non-steroidal antiestrogen, is widely used in adjuvant therapy for all stages of breast carcinomas and in chemoprevention of high-risk group. TAM also has estrogenic activity on liver and endometrium causing severe oxidative stress with various biochemical derangements. Coenzyme Q(10), Riboflavin and Niacin (CoRN) are well-known potent antioxidants and protective agents against many diseases including cancer. In this context, this study was undertaken to find if co-administration of TAM along with CoRN could alleviate the sole TAM-induced biochemical derangements in postmenopausal women with breast cancer.
METHOD: The vitamin supplementation with TAM was given for a period of 90 days. Blood samples were collected at the base line, 45th and 90th day during the course of treatment. Various blood chemistry profiles were assessed in 78 untreated, sole TAM treated and combinatorial treated group along with 46 age- and sex-matched controls.
RESULTS: A statistically significant alteration in various blood chemistry parameters, such as serum total bilirubin (S. BIL), serum glutamate oxaloacetate transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT), gamma glutamyl transpeptidase (gamma-GT), uric acid (UA), lipoprotein lipase (LPL), lecithin: cholesterol acyl transferases (LCAT), potassium, calcium and Na(+), K(+)-ATPase in sole TAM-treated group, was favorably reverted back to near normal levels on combinatorial therapy with CoRN.
CONCLUSION: TAM on co-administration with CoRN has a favorable impact on various blood chemistry profiles. However, large scale randomized studies over a longer time span are required to ascertain the safety and efficacy of co-administrating antioxidants with conventional chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18427979     DOI: 10.1007/s10549-008-0012-7

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  5 in total

1.  A pilot study of website information regarding aromatase inhibitors: dietary supplement interactions.

Authors:  Cara L McDermott; Angela A Hsieh; Erin S Sweet; Kimberly M Tippens; Jeannine S McCune
Journal:  J Altern Complement Med       Date:  2011-11       Impact factor: 2.579

2.  Adjuvant tamoxifen influences the lipid profile in breast cancer patients.

Authors:  Che Lin; Li-Sheng Chen; Shou-Jen Kuo; Dar-Ren Chen
Journal:  Breast Care (Basel)       Date:  2014-02       Impact factor: 2.860

Review 3.  [Complementary medicine in oncology].

Authors:  T Schnöller; R Küfer; T Eismann; L Rinnab
Journal:  Urologe A       Date:  2009-11       Impact factor: 0.639

4.  Effect of Dietary Niacin Supplementation on Growth Performance, Nutrient Digestibility, Hematology, and Lipoprotein Concentrations of Young Turkeys, Meleagris gallopavo.

Authors:  Tolulope Adebowale; Abimbola Oso; Hongnan Liu; Myrlene Tossou; Jiashun Chen; Huang Li; Baoju Kang; Kang Yao
Journal:  J Poult Sci       Date:  2019-04-25       Impact factor: 1.425

5.  Ubiquinol reduces gamma glutamyltransferase as a marker of oxidative stress in humans.

Authors:  Simone Onur; Petra Niklowitz; Gunnar Jacobs; Ute Nöthlings; Wolfgang Lieb; Thomas Menke; Frank Döring
Journal:  BMC Res Notes       Date:  2014-07-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.